Start-ups are developing transcatheter treatments for a type of heart failure that has been increasing in prevalence: heart failure with preserved ejection fraction. HFpEF is a huge potential device market because it appears to develop from an accumulation of damages that come with aging rather than a specific cause like heart attack or valve dysfunction.
In the early 50s, American surgeon Charles Hufnagel, MD began saving lives with a first-of-its-kind plastic aortic assist valve. Today, thanks to this pioneering work, transcatheter aortic valve implantation (TAVI) is firmly established as a safe and effective procedure for treating symptomatic patients with severe aortic stenosis. And, the transcatheter mitral valve repair (TMVR) space is advancing quickly.
“When One Door Closes Another Door Opens: The Story of Telluride Medical Partners.” Emerging Arizona-based medical device accelerator Telluride Medical Partners LLC (TMP) is comprised of business entrepreneurs, medical device start-up experts, and medtech engineers who are committed to bringing disruptive technologies to market. In this candid interview, Founder and CEO Eric Wells talks about his early career, his experiences in founding the company, and what’s next for TMP.
“Billy Cohn, MD: Making Medtech Makers at Johnson & Johnson’s CDI @TMC” In this candid video interview onsite at the Center for Device Innovation in Houston, TX, Billy Cohn, MD, VP of Johnson & Johnson’s Medical Device Companies and Director, CDI @ TMC reflects on his extensive device patent journey and shares the keys to overcoming the never-ending challenges that plague device innovation.
PAH, a progressive, incurable disease leading to right heart failure that strikes mostly women in the prime of life, has limited treatment options beyond some of the most expensive drugs covered by Medicare. TCT 2018 Shark Tank winner Aria CV hopes to impact the poor prognosis for this disease by focusing its first-of-a-kind, fully implantable device on a fundamental new mechanism of action—mimicking the function of a healthy pulmonary artery.
“FineHeart: A Disruptively Simple Solution for Advanced Heart Failure” France-based FineHeart SA aims to make an impact on the second leading cause of death in the US and in Europe: heart failure (HF) with its first patented product ICOMS. The ICOMS is a hybrid system composed of a pulsatile smart pump, an electrical synchronization module, a control board, and an energy module powered by a TET system. In this interview, CEO Arnaud Mascarell talks about his early inspiration, his experiences in co-founding the company and what’s next for FineHeart.
In this edition of “In MedTech History,” we take a look at heart failure, the reason for more hospitalizations of older Americans than any other condition. Researchers from MIT, Harvard University, Royal College of Surgeons in Ireland, Trinity College Dublin, the Advanced Materials and BioEngineering Research (AMBER) Center, and National University of Ireland Galway are developing a first-of-its-kind implant that they hope can deliver stem cells and other therapies directly to heart muscle damaged by myocardial infarction, and positively impact the cascade of events leading to heart failure.
Dublin-based start-up CroíValve is well on its way to making a significant impact on the emerging tricuspid valve repair market, with a 1st-place win at the MedTech Innovator Pitch Competition that took place at MedTech Strategist’s Innovation Summit global medical device investment and networking conference in Dublin, Ireland. In this candid interview onsite in Dublin with our own Associate Analyst Kayleen Brown, CEO Lucy O’Keeffe talks about her inspiration and early experiences in co-founding the company, her current priorities, and the surprises and lessons she has learned so far in her start-up journey.
An interview with Dr. Bernard Prendergast, director of PCR’s London Valves meeting, who points out how innovation in cardiology is rapidly changing worldwide to include technologies like digital health and AI, and even areas like bioresorbable scaffolds, which some thought dead, hold exciting prospects for the future.